Semiconductors

Dune Networks
Yakum, Israel, telecommunications chip developer Dune Networks raised $12 million in a Series B round of venture capital led by U.S. Venture Partners and including previous investors Alta Berkeley Ventures and Aurum Ventures, both of London; Cipio Partners of Germany; Jerusalem Venture Partners and Pitango Venture Capital of Germany; Siemens AG of Germany and other strategic investors. The funding comes on top of an initial round of $24 million in 2002, along with investment from partners, to bring total funding in the company to $45 million. Dune, which has a U.S. headquarters in Sunnyvale, Calif., will use the new capital to accelerate development of new network devices for data center, enterprise and carrier Ethernet markets. -- Clifford Carlsen

Software

NComputing
Desktop virtualization startup NComputing Inc. has raised a $28 million Series B financing. Menlo Ventures of Menlo Park, Calif., led the round, joined by insiders Scale Venture Partners of San Francisco and Daehong Technew Corp. of South Korea. The Redwood City, Calif., company makes virtualization software and hardware that allows up to 10 people to use a single PC from numerous terminals. NComputing plans to use the funds to expand its operations and sales organization globally as well as for product development. Much of the company's growth strategy involves making its technology available in countries where computer's are not necessarily commonplace. NComputing distributes its products to more than 70 countries and has offices in Australia, Canada, China, Germany, India, South Korea, Poland, Russia, the U.K. and the U.S.

Energy

Coskata
Biofuel startup Coskata Inc. of Warrenville, Ill., has received an undosclosed amount of capital as part of a new strategic partnership with General Motors Corp. The company had previously raised $15 million in venture funding from Khosla Ventures, Advanced Technology Ventures and GreatPoint Ventures.
Coskata has developed a biology-based technology for the production of ethanol for less than $1 per gallon.

Internet

Tremor Media
Online video advertising network Tremor Media has closed an $11 million Series B round for product development and expansion into Europe. New York-based Tremor Media's video advertising network allows advertisers to buy in-banner and in-stream video ads on Web site sites. Insiders Canaan Partners of Rowayton, Conn., and Masthead Venture Partners of Cambridge, Mass., led the round, which brought total funding for the company to $19.4 million. The two venture firms first backed Tremor with a $8.64 million Series A in September 2006.

Wireless equipment

Business Only Broadband
Business Only Broadband has closed its Series B round of financing with an undisclosed amount of capital. The Westmont, Ill.-based company is a provider of carrier-class wireless broadband services for companies in the financial sector. The round was led by Focus Equity Partners, LLC of Oak Brook, IL. The proceeds will be used as growth capital in the Chicago marketplace and for the company to expand into New York City. Founded in 2006, Business Only Broadband operates a wireless broadband network in the Chicago area.

Retail

Nueva Cocina
Nueva Cocina Foods Inc. of Miami has received a $2.25 million financing from Antares Capital Corp. of Melbourne, Fla., joined by New World Angels, a south Florida angel investor group. The proceeds will be used by Nueva Cocina to fund the company's expansion in the market for gourmet quality Latin cuisine products sold through major supermarket chains and independent grocers. The company's current product line includes rice mixes, soups and seasonings; and will be expanded to include a line of frozen foods.

Biopharmaceutical

Vivendy Therapeutics
Basel, Switzerland, biopharmaceutical startup Vivendy Tharapeutics Ltd.  raised Sfr17 million ($15 million) in a Series A financing from European venture investors BioMedInvest AG, LSP Life Science Partners and TVM Capital, it said Monday. The firm is developing an enzyme replacement therapy for Mucopolysaccharidosis, also known as MPS, Morbus Morquio or Morquio syndrome. Sufferers from this rare disease are at risk of heart failure, impaired vision and breathing problems and have skeletal deformations. The therapy would benefit from orphan drug status in the U.S., Europe and Japan. -- Jonathan Braude